Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

• Published in: The New England journal of medicine Vol. 366; no. 19; pp. 1759 - 1769
• Main Authors: Palumbo, Antonio, Hajek, Roman, Delforge, Michel, Kropff, Martin, Petrucci, Maria Teresa, Catalano, John, Gisslinger, Heinz, Wiktor-Jędrzejczak, Wiesław, Zodelava, Mamia, Weisel, Katja, Cascavilla, Nicola, Iosava, Genadi, Cavo, Michele, Kloczko, Janusz, Bladé, Joan, Beksac, Meral, Spicka, Ivan, Plesner, Torben, Radke, Joergen, Langer, Christian, Yehuda, Dina Ben, Corso, Alessandro, Herbein, Lindsay, Yu, Zhinuan, Mei, Jay, Jacques, Christian, Dimopoulos, Meletios A
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 10.05.2012
• Subjects: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Clinical trials; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunomodulation; Immunotherapy; Induction Chemotherapy; Induction therapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Melphalan - administration & dosage; Melphalan - adverse effects; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - mortality; Neoplasms, Second Primary - epidemiology; Neutropenia; Neutropenia - chemically induced; Patients; Prednisone; Prednisone - administration & dosage; Prednisone - adverse effects; Survival; Targeted cancer therapy; Thalidomide - administration & dosage; Thalidomide - adverse effects; Thalidomide - analogs & derivatives; Transplantation; Transplants & implants; Tumors

Patients treated with an induction regimen of melphalan, prednisone, and lenalidomide followed by lenalidomide maintenance therapy had longer progression-free survival than those who did not receive maintenance therapy. Melphalan–prednisone (MP) has long been the treatment of choice for patients wit...